Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsDenver-Health-Medical-Plan Prior Auth Coverage | O…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentDenver-Health-Medical-PlanPolicy H5608_PA26_C

    Prior Authorization Requirements — Specialty Pharmacy and Related Supplies

    Customize your policy alerts

    Sign up for Denver-Health-Medical-Plan Policy H5608_PA26_C alerts

    Get alerted when Policy H5608_PA26_C changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization criteria (age, prescriber, coverage duration, prerequisites, and other requirements) for listed specialty pharmacy drugs and related injection supplies under Denver-Health-Medical-Plan Elevate Medicare products. Affects prescribers and pharmacists submitting PA requests for the named products.

    Policy Summary
    PayerDenver-Health-Medical-Plan
    PolicyPrior Authorization Requirements — Specialty Pharmacy and Related Supplies
    Policy CodePolicy H5608_PA26_C
    Change TypeNo material change
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with required documentation (diagnostic tests, prior therapy trials, specialist consultation) per product-specific criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Multiple (≥30) productsdistinct products listed with PA criteria
    12 MONTHSmost coverage durations
    6 MONTHSsome initial durations
    Specialty/step notedprescriber/step requirements

    Coverage Criteria for Specialty Drugs

    TYMLOS initial/renewal

    TYMLOS (osteoporosis): covered when ALL of the following are met

    TYMLOS criteria: Coverage duration 24 months; patient has not received a total of 24 months cumulative treatment with any parathyroid hormone therapy; indication limited to FDA‑approved indications.24 months cumulative prior PTH therapy

    From product-specific fields.

    ORENCIA initial/renewal

    ORENCIA (and biosimilars/forms) — Initial and renewal criteria

    Prescriber restriction: Indications such as rheumatoid arthritis and polyarticular juvenile idiopathic arthritis must be prescribed by or in consultation with a rheumatologist; psoriatic arthritis by or in consultation with a dermatologist or rheumatologist.

    Prescriber specialty required for initiation.

    Policy Summary
    PayerDenver-Health-Medical-Plan
    PolicyPrior Authorization Requirements — Specialty Pharmacy and Related Supplies
    Policy CodePolicy H5608_PA26_C
    Change TypeNo material change
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with required documentation (diagnostic tests, prior therapy trials, specialist consultation) per product-specific criteria.
    SourceLink
    On This Page
    Coverage Criteria for Specialty DrugsProducts, Strengths, and CodingProvider Actions, Documentation, and Denial TriggersInitial Authorization RequirementsRenewal and Continuation RequirementsStep Therapy and Required Prior TrialsQuantity Limits and Pack SizesBackground and Policy ScopeDefinitions and Clinical Thresholds
    Prior therapy: Initial rheumatoid arthritis requires trial of or contraindication to 3 months of one conventional synthetic DMARD; if methotrexate was tried, trial must be at ≥20 mg/week or maximally tolerated dose.3 months; methotrexate ≥20 mg/week if tried

    Specific to RA initial therapy.

    No concurrent therapy: Initial and renewal: no concurrent use with another systemic biologic or targeted small molecule for the same indication; renewal requires continued benefit.

    Applies to initial and renewal requests.

    ARIKAYCE renewal and prescriber requirements

    ARIKAYCE (MAC lung disease) renewal criteria

    Microbiology: First renewal requires at least one negative Mycobacterium avium complex (MAC) sputum culture by six months of ARIKAYCE treatment; second and subsequent renewals require at least three negative MAC sputum cultures by 12 months; renewal also requires improvement in symptoms and no positive MAC sputum cultures after consecutive negatives.1 negative by 6 months (first renewal); 3 negatives by 12 months (subsequent)

    Also requires clinical improvement in symptoms.

    Prescriber: Initial therapy must be prescribed by or in consultation with a pulmonologist or infectious disease specialist for MAC lung disease.

    Prescriber restriction for initial approvals.

    Prostate cancer therapy prerequisites

    Androgen-axis targeted therapies for prostate cancer

    Castration requirement: For metastatic high-risk castration-sensitive prostate cancer or metastatic castration-resistant prostate cancer require one of: bilateral orchiectomy; castrate testosterone level (<50 ng/dL); or concurrent use with a gonadotropin releasing hormone (GnRH) analog.testosterone <50 ng/dL

    Applies to abiraterone, YONSA and similar products as specified.

    General biologic/immunomodulator criteria

    Biologic and immunomodulator initiation/renewal general rules

    Disease severity or trial requirements: Initial psoriasis or psoriatic disease often requires defined body surface area (BSA) or severity metrics (e.g., BSA ≥3% or special-site involvement) or prior trials of topical/systemic therapies or phototherapy as specified per product.BSA thresholds 2–3% mentioned depending on product

    Several products specify 3% BSA for plaque psoriasis; mild PSO definitions also provided.

    Prescriber specialties: Many indications require prescription by or consultation with a specialty provider (rheumatologist, dermatologist, gastroenterologist, ophthalmologist) depending on the diagnosis.

    Common across multiple products.

    Renewals typically require documented continued clinical benefit and no concurrent use with another systemic biologic or targeted small molecule for the same indication; renewal durations commonly 12 months.

    Renewal requirements commonly 12 months.

    Initial Psoriasis Therapy

    Psoriasis initial coverage — distinct eligibility logic for mild vs moderate-to-severe disease

    Mild plaque psoriasis eligibility: Covered when ANY of the following are met: (1) psoriasis covering approximately 2% body surface area (BSA), (2) Static Physician Global Assessment (SPGA) score of 2, OR (3) Psoriasis Area and Severity Index (PASI) score of 2 to 9.BSA ~2% OR SPGA=2 OR PASI 2-9

    Initial coverage duration 6 months; renewal 12 months.

    Moderate-to-severe psoriasis eligibility: Covered when ANY of the following are met: (1) psoriasis covering 3% or more BSA, OR (2) psoriatic lesions affecting hands, feet, face, scalp, or genital area.BSA >=3% or special site involvement

    Requires prescriber who is or consulted with a dermatologist; prior therapy trials required as specified.

    Prior therapy and concurrent therapy exclusions

    General concurrent therapy exclusion and prior treatment requirements

    No concurrent systemic biologic/targeted therapy: No concurrent use with another systemic biologic or targeted small molecule (e.g., JAK inhibitor, PDE-4 inhibitor) for the same indication; applies to initial and renewal requests.

    Applies broadly across products.

    Prior therapy requirements - mild PSO: Mild psoriasis: trial of or contraindication to one conventional systemic therapy (e.g., methotrexate, acitretin, cyclosporine) OR one conventional topical therapy (e.g., topical corticosteroids).
    Prior therapy requirements - moderate-to-severe PSO: Moderate-to-severe psoriasis: at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA phototherapy; OR contraindication/intolerance to both; OR switching from another biologic, PDE-4 inhibitor, or JAK inhibitor for same indication.3 months trial

    Hypophosphatasia (Strensiq) criteria

    Strensiq (enzyme replacement) initiation and renewal criteria

    Perinatal/infantile-onset HPP: Initial: onset at 6 months of age or younger AND positive TNSALP (ALPL) gene mutation by genetic testing OR two of the listed biochemical/radiographic/clinical findings (low serum ALP, elevated PLP without recent B6 supplement, elevated urine PEA, radiographic evidence of HPP, rachitic chest deformity, craniosynostosis, delayed motor development, history of vitamin B6-dependent seizures, nephrocalcinosis/elevated serum calcium, non‑traumatic postnatal fracture/delayed healing).age <=6 months plus genetic or 2+ findings

    Initial duration 6 months; renewal 12 months; renewal requires improvement in skeletal characteristics and not receiving bisphosphonate.

    Juvenile-onset HPP: Initial: onset at 18 years or younger AND positive TNSALP (ALPL) gene mutation by genetic testing OR two of the listed findings (low serum ALP, elevated PLP without recent B6 supplement, elevated urine PEA, radiographic evidence, rachitic deformities, premature loss of primary teeth before age 5, delayed motor development, non‑traumatic fractures/delayed healing).age <=18 years plus genetic or 2+ findings

    Additional exclusion: must not have treatable rickets; renewal requires improvement and no bisphosphonate use.

    ANCA-associated vasculitis (Tavneos)

    Tavneos for ANCA-associated vasculitis

    Tavneos initiation: Initial: ANCA-associated vasculitis with ANCA seropositivity (anti‑PR3 or anti‑MPO) AND prescribed by or in consultation with a rheumatologist or nephrologist.ANCA seropositive

    Initial/renewal duration 6 months; renewal requires continued benefit.

    PAH criteria for bosentan

    Bosentan for pulmonary arterial hypertension (PAH)

    PAH diagnostic confirmation: Initial: diagnosis confirmed by right heart catheterization with mean pulmonary artery pressure (PAP) >20 mmHg, pulmonary capillary wedge pressure (PCWP) ≤15 mmHg, and pulmonary vascular resistance (PVR) >2 Wood units; must not have ALT/AST >3× ULN or bilirubin increase ≥2× ULN; no concurrent use with cyclosporine A or glyburide.hemodynamic criteria and liver enzyme limits

    Prescribed by or in consultation with cardiologist or pulmonologist; initial/renewal 12 months.

    Asthma and EGPA (Fasenra) criteria

    Fasenra (benralizumab) asthma and EGPA criteria

    Asthma eligibility: Initial: blood eosinophils ≥150 cells/mcL within the past 12 months; patient must be on medium/high‑dose or maximally tolerated inhaled corticosteroid (ICS) plus one other maintenance medication AND have either an exacerbation requiring systemic corticosteroid burst ≥3 days in past 12 months, or hospitalization/ER visit for exacerbation in past 12 months, OR poor symptom control evidenced by at least three specified symptoms in past 4 weeks.eosinophils >=150 cells/mcL; ICS + maintenance therapy

    Prescribed by or in consultation with allergy/pulmonary specialist; initial/renewal 12 months; renewal requires continued ICS+maintenance and clinical response metrics.

    EGPA eligibility: EGPA: renewal requires clinical improvement or ability to reduce/eliminate corticosteroids compared to baseline.clinical response

    Applies to EGPA indication.

    Benlysta criteria

    Benlysta (subcutaneous) for SLE and lupus nephritis

    SLE initiation prerequisites: Initial: prescribed by or in consultation with a rheumatologist; patient is currently taking corticosteroids, antimalarials, NSAIDs, or immunosuppressive agents.

    Initial duration 6 months; renewal 12 months and requires clinical improvement.

    Lupus nephritis initiation prerequisites: Initial: prescribed by or in consultation with a rheumatologist or nephrologist; renewal requires improvement in renal response from baseline labs (eGFR or proteinuria) and/or clinical parameters.

    Hereditary angioedema (HAEGARDA)

    Hereditary angioedema (HAEGARDA) prophylaxis

    HAE diagnostic confirmation: Initial: diagnosis confirmed by complement testing (C1‑INH protein levels, C4 protein levels, C1‑INH functional levels, or C1Q) and prescribed by or in consultation with a hematologist, immunologist, allergist, or pulmonologist; patient must not be on concurrent alternative prophylactic agent for HAE attacks.complement test confirmation

    Initial/renewal 12 months; renewal requires reduction in attack frequency/severity and not on concurrent prophylactic agent.

    Scemblix (CML) criteria

    Scemblix for Ph+ CML

    Scemblix T315I or previously treated Ph+ CML: Mutational analysis (BCR‑ABL1 mutation profile) required prior to initiation for previously treated disease or T315I‑mutant Ph+ CML; Scemblix use must align with NCCN guidance for mutation‑directed therapy.mutational analysis per NCCN

    Coverage duration 12 months.

    Epidiolex criteria

    Epidiolex for specific epilepsy syndromes

    Epidiolex initiation: Initial: for Dravet syndrome, Lennox‑Gastaut syndrome, and tuberous sclerosis complex must be prescribed by or in consultation with a neurologist; for Lennox‑Gastaut syndrome initial requires trial of or contraindication to two listed antiepileptic medications (rufinamide, felbamate, clobazam, topiramate, lamotrigine, clonazepam).trial of 2 AEDs for LGS

    Initial/renewal 12 months; prerequisite therapy required for some indications.

    EPIDIOLEX Initial Therapy

    EPIDIOLEX initial requirements

    EPIDIOLEX Initial: Prescribed for Dravet syndrome, Lennox‑Gastaut syndrome, or tuberous sclerosis complex; prescribed by or in consultation with a neurologist; coverage duration initial/renewal 12 months; for LGS initial: trial of or contraindication to two listed antiepileptic medications.

    Specialty Biologic/Targeted Agent Criteria

    Biologic/targeted agents for rheumatologic, dermatologic, and GI indications

    Initial: Prescribed by or in consultation with the specialty provider appropriate to the indication (rheumatologist, dermatologist, gastroenterologist); trial of or contraindication to a specified number of preferred agents is required per indication (counts and agent lists vary by diagnosis); initial coverage typically 6 months with renewal 12 months.

    No concurrent use with another systemic biologic or targeted small molecule for same indication.

    Carglumic acid Coverage Criteria

    Carglumic acid indications and duration

    Carglumic acid: Covered for acute or chronic hyperammonemia due to NAGS deficiency, acute hyperammonemia due to propionic acidemia (PA), or methylmalonic acidemia (MMA) with required biochemical or genetic confirmation; coverage durations: acute hyperammonemia due to NAGS/PA/MMA: 7 days; chronic hyperammonemia due to NAGS initial 6 months, renewal 12 months with requirement of clinical improvement for chronic NAGS.

    Diagnosis confirmation via biochemical or genetic testing required.

    Droxidopa (NOH) Criteria

    Droxidopa for NOH

    Droxidopa Initial: Baseline sitting and standing blood pressure readings documented and orthostatic drop meeting threshold (decrease ≥20 mmHg systolic or ≥10 mmHg diastolic within three minutes of standing) demonstrated; prescribed by or in consultation with a neurologist or cardiologist; initial coverage 3 months; renewal 12 months with documented continued benefit.>=20 mmHg systolic OR >=10 mmHg diastolic within 3 minutes

    Baseline vitals required for initial approval.

    Droxidopa initial approval criteria

    Droxidopa — Neurogenic orthostatic hypotension (NOH) initial criteria

    Droxidopa initial: 1) Baseline blood pressure readings while sitting and also within 3 minutes of standing from a supine position; 2) A decrease of at least 20 mmHg systolic blood pressure or 10 mmHg diastolic blood pressure within three minutes after standing from a sitting position.see node text

    Prescribed by or in consultation with a neurologist or cardiologist for initial therapy; initial coverage 3 months, renewal 12 months.

    Orilissa initial approval criteria

    Orilissa — moderate to severe endometriosis pain initial criteria

    Orilissa initial: Diagnosis confirmed via surgical or direct visualization (e.g., pelvic ultrasound) or histopathological confirmation (e.g., laparoscopy or laparotomy) within the last 10 years; patient is 18 years or older; prescribed by or in consultation with an OB/GYN; no concurrent use with another GnRH‑modulating agent; trial of or contraindication to an NSAID and a progestin‑containing preparation.diagnosis within 10 years

    Initial coverage 6 months; renewal 12 months contingent on improvement and no concurrent GnRH agent.

    Alvaiz ITP initial criteria

    Alvaiz (eltrombopag) — persistent or chronic immune thrombocytopenia (ITP) initial criteria

    Alvaiz ITP initial: Platelet count <30 ×10^9/L from at least two separate labs in the last 3 months, OR platelet count <50 ×10^9/L from at least two separate labs in the last 3 months AND prior bleeding event; trial of or contraindication to one corticosteroid or immunoglobulin, or insufficient response to splenectomy; no concurrent use with other thrombopoietin receptor agonists (TPO‑RAs) or SYK inhibitors.platelet thresholds as stated

    Initial coverage 6 months; renewal 12 months with evidence of benefit and no concurrent agents.

    Revcovi diagnostic and renewal criteria

    Revcovi — ADA-SCID initial criteria

    Revcovi ADA-SCID diagnostic: Confirmatory genetic test for ADA‑SCID OR suggestive laboratory findings (e.g., elevated deoxyadenosine nucleotide levels, lymphopenia) combined with hallmark signs/symptoms (recurrent infections, failure to thrive, persistent diarrhea).diagnostic tests as stated

    Initial coverage 6 months; renewal 12 months; renewal requires improvement or maintenance of immune function and not having received successful hematopoietic cell transplant or gene therapy.

    VOWST CDI criteria

    VOWST — Clostridioides difficile infection (CDI) criteria

    VOWST initial/retreatment: Initial: patient has not previously received VOWST and has completed antibiotic treatment for recurrent CDI (at least 3 CDI episodes); OR if previously received VOWST: treatment failure defined as CDI diarrhea within 8 weeks of first dose with a positive stool test AND has not received more than one treatment course of VOWST which was at least 12 days and not more than 8 weeks prior.timing and episode counts as stated

    Coverage duration 30 days.

    Fintepla prerequisite therapy

    Fintepla — seizure disorder criteria

    Fintepla initial: For Lennox‑Gastaut syndrome (LGS): trial of or contraindication to two of the specified antiepileptic medications (rufinamide, felbamate, clobazam, topiramate, lamotrigine, clonazepam) before initial approval; prescriber for Dravet/LGS initial must be a neurologist or in consultation with a neurologist.trial of two AEDs

    Coverage durations: Dravet initial/renewal 12 months; LGS 12 months.

    Elrexfio renewal criteria

    Elrexfio — relapsed or refractory multiple myeloma renewal criteria

    Elrexfio renewal: Renewal requires the patient has received at least 24 weeks (≈24 weeks) of treatment with Elrexfio and has responded to treatment (partial response or better) and has maintained this response for at least 2 months.>=24 weeks treatment and >=2 months maintained response

    Initial coverage 6 months; renewal 12 months.

    VOWST (for Clostridioides difficile infection)

    Covered when criteria below are met

    Indication branches: (1) Patient has NOT previously received VOWST and has completed antibiotic treatment for recurrent CDI (at least 3 CDI episodes) OR (2) Patient has previously received VOWST and meets BOTH: treatment failure (presence of CDI diarrhea within 8 weeks of first dose of VOWST and positive stool test) AND has not received more than one treatment course of VOWST which was at least 12 days and not more than 8 weeks prior.

    Coverage duration 30 days.

    VYALEV (Parkinson's disease)

    Initial approval requires ALL of the following

    Initial VYALEV criteria: 1) Patient is responsive to levodopa; 2) current regimen includes at least 400 mg/day of levodopa; 3) motor symptoms are uncontrolled (average off time ≥2.5 hours/day over 3 consecutive days, minimum 2 hours each day); and 4) either (A) unable to swallow extended‑release tablets or administer ER capsules via feeding tube, OR (B) failure to adhere or tolerate oral carbidopa/levodopa via feeding tube.

    Initial duration 3 months; renewal requires improvement in motor symptoms.

    Biologics (examples: TREMFYA, infliximab, others)

    Covered when ALL of the following are met (varies by drug/indication)

    Typical biologic/targeted therapy criteria: Initial: prescriber specialty restrictions may apply; specified trial(s) of or contraindication(s) to listed preferred agents are required for many indications (counts and lists vary by diagnosis); no concurrent use with another systemic biologic or targeted small molecule for the same indication. Duration: initial commonly 6 months, renewal 12 months with documented continued benefit for certain indications.

    Specific agent‑level exceptions and additional required trials vary by drug and indication as listed in product entries.

    ZOLADEX (endometriosis and other indications)

    Covered when criteria below are met

    Endometriosis-specific criteria: 1) Diagnosis confirmed via surgical/direct visualization or histopathology within last 10 years; 2) prescribed by or in consultation with an OB/GYN; 3) trial of or contraindication to an NSAID and a progestin‑containing preparation; additionally, therapy for endometriosis is limited to a total of 6 months per lifetime and no concurrent use with another GnRH‑modulating agent.6 months per lifetime for endometriosis

    Other indications have separate duration rules (e.g., prostatic carcinoma 4 months).

    Icatibant (Hereditary angioedema)

    Covered when criteria below are met

    HAE confirmation: Diagnosis of hereditary angioedema must be confirmed by one of the following complement tests: C1‑INH protein levels, C4 protein levels, C1‑INH functional levels, or C1Q; prescribed by or in consultation with an allergist, immunologist, hematologist, or pulmonologist for initial requests.

    Initial/renewal 12 months; no concurrent use with other medications for acute HAE attacks.

    KINERET (anakinra) is explicitly excluded for the indication of COVID-19 in hospitalized adults. Requests for anakinra to treat hospitalized adult patients with COVID-19 should be denied per this exclusion.

    Concurrent use of a systemic biologic or a targeted small molecule for the same indication is not permitted. The policy states no concurrent use with another systemic biologic or targeted small molecule (e.g., JAK inhibitor, PDE‑4 inhibitor) for the same indication; such concurrent therapy may trigger denial or be considered not medically necessary.

    For MAVENCLAD (cladribine), cumulative exposure is limited: patients with relapsing multiple sclerosis who have already received a total of two years of Mavenclad treatment (two yearly treatment courses) are excluded from additional treatment under this policy.

    Certain specific formulations intended for patients unable to swallow capsules are restricted to the indicated use. For example, the XALKORI oral pellet presentation is listed only for patients who are unable to swallow capsules; requests for alternate uses of pellet formulations outside that stated indication should not be approved.

    Orilissa (elagolix) initial therapy requires objective diagnostic confirmation of endometriosis. The policy requires diagnosis by surgical or direct visualization (e.g., laparoscopy, laparotomy, or pelvic imaging) or histopathology within the prior 10 years, and an OB/GYN prescriber or consultation for initial requests before authorization is granted.

    VOWST (fecal microbiota, live-jslm) coverage is limited to specified recurrent CDI scenarios and to treatment-course limits. Initial coverage is for patients who have completed antibiotic treatment for recurrent CDI (typically at least 3 CDI episodes), and retreatment is allowed only when defined failure criteria are met; the policy also restricts prior exposure by specifying that the patient must not have received more than one prior VOWST treatment course within the timing limits stated.

    Across the policy, concurrent systemic therapy with another biologic or targeted small molecule for the same indication is prohibited. Renewal and initial approvals require that the patient is not receiving another systemic biologic or targeted small molecule (examples cited include JAK inhibitors and PDE‑4 inhibitors); concurrent therapy may be a trigger for denial.

    Products, Strengths, and Coding

    NDCNDC
    100 MGProduct strength — 100 mg
    200 MGProduct strength — 200 mg
    NDCNDC
    100 MGProduct strength — 100 mg
    200 MGProduct strength — 200 mg
    NDCNDC
    100 MGProduct strength — 100 mg
    200 MGProduct strength — 200 mg
    Pack descriptorsmixed
    0.5 MLsyringe pack descriptor
    1 MLsyringe pack descriptor
    Device SKUsmixed
    TECHLITE 0.3 ML 31GX6MMsyringe SKU
    TECHLITE 0.3 ML 31GX8MMsyringe SKU
    SAFESNAP INS SYR UNITS-100 0.5 MLsafety syringe SKU
    Products Affectedmixed
    DUPIXENT PENDevice
    DUPIXENT SYRINGEDevice
    SYMPAZANProduct
    COTELLICProduct
    droxidopaProduct
    Syringe SKUsmixed
    SURE-JECT INSUL SYR U100 0.5 MLsyringe
    SURE-JECT INSUL SYR U100 1 MLsyringe
    TECHLITE 0.5 ML 30GX12MMsyringe
    TECHLITE 0.3 ML 31GX8MMsyringe
    Key clinical thresholds

    Provider Actions, Documentation, and Denial Triggers

    Documentation Required

    Provider Action — Key Authorization & Documentation Notes

    Prior authorization requirements and documentation vary by product. Many biologic and targeted therapies include an explicit requirement that there be no concurrent use with another systemic biologic or targeted small molecule for the same indication. For products where documentation, step therapy, or explicit authorization/denial rules are not specified in the source chunks, no additional authorization steps or documentation instructions are provided in this section — reviewers should presume standard prior authorization submission (diagnosis, relevant labs/imaging, prior therapy history) unless product-specific requirements are listed elsewhere in the policy.

    • No concurrent systemic biologic/targeted small molecule: Several products (e.g., ORENCIA, multiple psoriasis/autoimmune biologics, asthma biologics, and others listed) include an explicit prohibition on concurrent use with another systemic biologic or targeted small molecule (e.g., JAK inhibitors, PDE-4 inhibitors) for the same indication.
    • Missing / not specified items: Many chunks do not include explicit authorization or denial triggers, documentation instructions, or step therapy rules; where the source is silent, there are no additional provider-action steps described in this section.
    • Product identifiers and packaging detail: For syringe/insulin injection supplies and related items, detailed product identifiers and packaging/SKU information are listed (pen needles, syringe sizes, needle gauges).
    Documentation Required

    Documentation — When to Include Supporting Evidence

    Where product-specific documentation requirements are listed in the policy (for example: mutational analysis for Scemblix; genetic/biochemical confirmation for Strensiq; baseline vitals for droxidopa; culture results for ARIKAYCE; diagnostic confirmation for carglumic acid; prior CDI antibiotic treatment and failure criteria for VOWST), those requirements must be submitted with the PA request. If a product entry does not list documentation instructions or authorization/denial criteria, no additional documentation requirements are specified here.

    • Submit product-specific supporting documentation when explicitly required by the product entry (labs, genetic tests, imaging, specialist consultation notes, prior treatment trials).
    • If renewal criteria are listed (e.g., continues to benefit, negative cultures, improvement in disease markers), include evidence to support continued benefit.
    • No explicit denial triggers listed: Several chunks do not contain explicit denial triggers; absence of a listed denial condition does not remove the need to meet any stated inclusion/exclusion criteria.
    Step Therapy

    Step Therapy / Prior Trials

    Step therapy and prior trial requirements are specified only for products where noted (examples include conventional synthetic DMARD trials for RA, trials of oral immunosuppressants or phototherapy for psoriasis, prior antiemetic for dronabinol, prior AEDs for Fintepla, trial of JAKAFI for Inrebic, etc.). For many products and syringe/insulin supply listings, no step therapy rules are provided in these chunks.

    • When step therapy is required, document prior agents tried, dates, doses, and reason for discontinuation (failure, intolerance, or contraindication).
    • If the chunk contains no step therapy requirement, none is specified in this section for that product.
    Denial Risk

    Denial Risk — What Triggers Potential Denial

    Denial risk arises if required product-specific criteria are not met (e.g., lack of required genetic testing, absence of specialist consultation when required, concurrent use of disallowed therapies, or failure to show continued benefit at renewal). However, many chunks do not list explicit denial triggers; reviewers should apply the listed inclusion/exclusion and "no concurrent use" rules and request missing documentation before denial where appropriate.

    • Denial may be appropriate when the product-specific inclusion/exclusion criteria are not satisfied (e.g., missing diagnostic confirmation, required lab thresholds not met, or prohibited concurrent therapy present).
    • When the policy chunk is silent on denial triggers, there is no additional explicit denial rule in this section beyond meeting the stated criteria.

    Initial Authorization Requirements

    Initial therapy nodes

    Initial therapy requirements vary by product/indication

    ORENCIA initial RA: Trial of or contraindication to 3 months of one conventional synthetic DMARD; if methotrexate tried, trial at ≥20 mg/week or maximally tolerated dose; prescriber specialty (rheumatologist) required.3 months; methotrexate ≥20 mg/week if tried

    Prescriber specialty required.

    Psoriasis initial: Plaque psoriasis initial typically requires psoriasis covering ≥3% BSA or lesions affecting hands/feet/face/scalp/genital area, or other defined severity measures depending on product.BSA ≥3% or specific lesion locations

    Some products list 2% BSA for mild PSO definitions.

    KYNMOBI initial PD: KYNMOBI initial use for Parkinson's disease requires patient age ≥18 and prescription by or in consultation with a neurologist; initial coverage 6 months.age ≥18

    Renewal requires improvement in motor fluctuations.

    Initial therapy prerequisites

    Initial therapy commonly requires prior trial or contraindication to standard/conventional therapies and specialist prescribing.

    Psoriasis initial therapy prerequisites: Mild psoriasis: trial of or contraindication to one conventional systemic or one conventional topical therapy. Moderate‑to‑severe psoriasis: at least 3‑month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA phototherapy, or contraindication/intolerance to both, or switching from another biologic/PDE‑4/JAK for same indication; prescriber must be or consult a dermatologist.3 months for moderate‑severe

    Biologic concurrent‑use exclusions apply.

    Initial biologic/specialty agent therapy

    Initial requirements for biologics and select specialty agents

    Initial biologic approval: Prescriber specialty requirement per indication; trial of or contraindication to specified preferred agents required (counts and lists vary by diagnosis); initial coverage durations often 6 months. Step agent requirements may be waived for pregnancy, breastfeeding, or trying to conceive as specified.

    Step agent details vary by drug and indication.

    Orilissa initial therapy

    Orilissa initial therapy

    Orilissa initial: Diagnosis confirmation within 10 years; age ≥18; OB/GYN prescriber or consult; trial or contraindication to NSAID and progestin‑containing preparation; no concurrent GnRH agent.10 years; age >=18

    Initial coverage 6 months.

    Revcovi initial therapy

    Revcovi initial therapy

    Revcovi initial: Confirmatory genetic test for ADA‑SCID OR suggestive laboratory findings plus hallmark signs/symptoms (recurrent infections, failure to thrive, persistent diarrhea).diagnostic as stated

    Initial coverage 6 months; renewal 12 months.

    Initial therapy examples

    Initial authorization rules (examples)

    FINTEPLA for LGS: Initial requires prescription by or in consultation with a neurologist and trial of or contraindication to two other antiepileptic drugs (rufinamide, felbamate, clobazam, topiramate, lamotrigine, clonazepam).

    Initial and renewal durations specified (12 months).

    Renewal and Continuation Requirements

    Renewal requirements

    Renewal common requirements for immunomodulators

    Continued benefit: Renewal requires evidence that the patient continues to benefit from the medication.

    Stated for multiple products (e.g., ORENCIA, various biologics).

    No concurrent therapy: Renewal requires no concurrent use with another systemic biologic or targeted small molecule for the same indication.

    Repeated across many products.

    Continuation/renewal overview

    Continuation/renewal overview

    General renewal: Renewal typically 12 months and requires evidence of continued benefit from the medication and no concurrent systemic biologic/targeted small molecule for the same indication.renewal 12 months; continued benefit

    Some agents have 6‑month initial periods before 12‑month renewals.

    Carglumic acid continuation

    Carglumic acid continuation

    Chronic NAGS Renewal: For chronic hyperammonemia due to NAGS deficiency: renewal requires that the patient has shown clinical improvement.

    Renewal coverage 12 months.

    Biologics continuation

    Biologics continuation

    RA/PSA/AS/PSO/NR-AXSPA/PJIA Renewal: Renewal requires that the patient continues to benefit from therapy (clinical improvement or maintenance of response).

    Renewal durations commonly 12 months.

    Elrexfio continuation

    Elrexfio renewal requirements

    Elrexfio continuation: Patient has received at least 24 weeks of Elrexfio and demonstrated a partial response or better maintained for at least 2 months.24 weeks treatment; 2 months maintained response

    Renewal duration 12 months.

    Renewal rules

    Renewal/continuation criteria

    Renewal general: Renewal typically requires evidence of continued clinical benefit (examples: VYALEV requires improvement in motor symptoms; many biologics require continued benefit for RA/PSO/PSA).

    Renewal durations commonly 12 months after initial authorization.

    Step Therapy and Required Prior Trials

    IndicationRequired prior trial(s) / stepNotes
    Rheumatoid arthritis (RA)Trial of or contraindication to TWO preferred agents: HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIANo concurrent use with another systemic biologic or targeted small molecule; renewal requires continued benefit
    Psoriatic arthritis (PSA)Trial of or contraindication to TWO preferred agents: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA, SELARSDI/YESINTEK, XELJANZ, RINVOQ, SKYRIZI, TREMFYA, ORENCIA, OTEZLAPrescriber specialty (rheumatologist or dermatologist) may be required; no concurrent systemic biologic/targeted small molecule
    Ankylosing spondylitis (AS)Trial of or contraindication to TWO preferred agents: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQNo concurrent use with another systemic biologic or targeted small molecule
    Psoriasis severityRequired prior trial(s)Notes
    Mild plaque psoriasisTrial of or contraindication to ONE conventional systemic therapy (e.g., methotrexate, acitretin, cyclosporine) OR ONE conventional topical therapy (e.g., topical corticosteroids)No concurrent use with another systemic biologic/targeted small molecule; initial coverage typically 6 months
    Moderate-to-severe plaque psoriasisAt least a 3-month trial of ONE oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) OR PUVA phototherapy; OR contraindication/intolerance to both; OR switching from another biologic/PDE‑4/JAKPrescribed by or in consultation with a dermatologist; initial 6 months, renewal 12 months
    Therapy typeRequired prior trial(s)Notes
    Conventional synthetic DMARD (RA)Trial of or contraindication to 3 months of one conventional synthetic DMARD; if methotrexate tried, require trial at ≥20 mg/week or maximally tolerated doseApplies to initial RA prior to biologic initiation
    Conventional systemic agents (psoriasis)At least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA phototherapyRequired for moderate-to-severe psoriasis before biologic approval
    Topical therapy (mild psoriasis)Trial of or contraindication to one conventional topical therapy (e.g., topical corticosteroids)Acceptable alternative for mild plaque psoriasis prior to systemic/biologic therapy
    Preferred agent categoryNumber of preferred-agent trials requiredExamples / notes
    RA (preferred biologic/small-molecule agents)Two preferred-agent trials (or contraindication)Preferred examples include HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA; step may be waived for pregnancy/breastfeeding/trying to conceive
    PSA / PSO / ASTwo preferred-agent trials (or contraindication)Preferred lists vary by indication (see product-specific lists such as COSENTYX, TREMFYA, SKYRIZI, etc.); no concurrent systemic biologic/targeted small molecule
    Crohn's disease / Ulcerative colitisOne or two preferred-agent trials depending on age/indication (per product)Examples include SELARSDI/YESINTEK, HUMIRA/CYLTEZO/YUFLYMA, RINVOQ, SKYRIZI, TREMFYA; check indication-specific requirements
    RequirementPrior trial requiredPolicy detail / notes
    DMARD prior to biologic for RATrial of or contraindication to 3 months of one conventional synthetic DMARDIf methotrexate tried, require trial at ≥20 mg/week or maximally tolerated dose before biologic therapy
    IndicationRequired prior therapiesNotes
    Moderate to severe endometriosis pain (Orilissa)Trial of or contraindication to an NSAID AND a progestin-containing preparationDiagnosis confirmed by surgical/direct visualization or histopathology within last 10 years; patient ≥18 years; no concurrent GnRH‑modulating agent; initial 6 months, renewal 12 months
    IndicationRequired prior AED trialsNotes
    Lennox‑Gastaut syndrome (LGS) — Fintepla prerequisiteTrial of or contraindication to TWO of the following antiepileptic medications: rufinamide, felbamate, clobazam, topiramate, lamotrigine, clonazepamPrescribed by or in consultation with a neurologist for initial approval; coverage duration 12 months
    Common scenarioPreferred-agent trials requiredNotes
    Initial approval for many rheumatologic/dermatologic/GI biologicsTrial of or contraindication to TWO preferred agents is commonly requiredExamples: RA, PSA, PSO, CD, UC frequently require two preferred-agent trials; no concurrent systemic biologic/targeted small molecule
    Some indications (e.g., Crohn's disease)Trial of ONE preferred agent may be required depending on indication and ageCheck product-specific lists; step requirements may be waived for pregnancy/breastfeeding/trying to conceive

    Quantity Limits and Pack Sizes

    SAFESNAP INS SYR UNITS-100
    Pack descriptorSAFESNAP INS SYR UNITS-100 = unit/pack descriptor used for affected syringe listings
    Typical volumes listedAppears with 0.3 mL, 0.5 mL, and 1 mL syringe entries in product lists
    Usage contextListed among products affected subject to prior authorization for insulin injection supplies

    Background and Policy Scope

    This policy groups specialty products with drug-specific clinical prerequisites and prior‑authorization requirements. It emphasizes three recurring elements: (1) many specialty agents require a prescriber who is a specialist or who consults with a specialist for initiation, (2) prior trials or contraindications to conventional therapies or specified preferred agents are commonly required before biologic or targeted therapies will be approved, and (3) renewals generally require documented continued clinical benefit and avoidance of concurrent systemic biologic or targeted small‑molecule therapy. Coverage durations are product‑specific but commonly include an initial authorization (often 3–6 months) followed by renewal periods of 12 months when benefit is demonstrated.

    Definitions and Clinical Thresholds

    MAC (Mycobacterium avium complex)
    DefinitionMAC (Mycobacterium avium complex): renewal requires absence of positive MAC sputum cultures after consecutive negatives and clinical improvement
    First renewal microbiologyAt least one negative MAC sputum culture by six months of ARIKAYCE treatment required for first renewal
    Subsequent renewals microbiologyAt least three negative MAC sputum cultures by 12 months required for second and subsequent renewals
    DMARD definition
    DefinitionDMARD = conventional synthetic disease‑modifying antirheumatic drug (examples include methotrexate)
    RA prior-therapy implicationInitial RA requires trial of or contraindication to 3 months of one conventional synthetic DMARD (e.g., methotrexate)
    Methotrexate dosing expectationIf methotrexate tried, a trial at ≥20 mg/week or maximally tolerated dose is required
    SPGA score
    SPGA termSPGA = Static Physician Global Assessment (score used in psoriasis severity criteria)
    SPGA threshold in policySPGA score of 2 used as one criterion for mild plaque psoriasis eligibility
    Context of useAppears as alternative to BSA or PASI for determining mild disease eligibility
    PASI score
    PASI termPASI = Psoriasis Area and Severity Index (score used in psoriasis severity criteria)
    PASI thresholds in policyPASI score of 2–9 qualifies as mild plaque psoriasis for initial coverage
    RoleUsed alongside BSA and SPGA as an eligibility metric
    Acute hyperammonemia due to NAGS/PA/MMA
    DefinitionAcute hyperammonemia due to NAGS/PA/MMA: requires biochemical or genetic confirmation (NAGS gene mutation; PA with elevated methylcitric acid and normal methylmalonic acid or PCCA/PCCB mutation; MMA with elevated methylmalonic/methylcitric acid or genetic confirmation)
    Coverage duration (acute)Acute HA due to NAGS/PA/MMA: coverage duration 7 days
    Chronic NAGS coverageChronic HA due to NAGS initial: 6 months; renewal: 12 months with evidence of clinical improvement
    Neurogenic orthostatic hypotension (NOH)
    NOH diagnostic BP requirementRequires baseline seated and standing blood pressure readings demonstrating a ≥20 mmHg systolic or ≥10 mmHg diastolic drop within three minutes of standing
    PrescriberInitial NOH therapy prescribed by or in consultation with a neurologist or cardiologist
    Coverage durationsInitial: 3 months; Renewal: 12 months with documented continued benefit
    VOWST failure definition
    VOWST failure definitionTreatment failure = presence of CDI diarrhea within 8 weeks of first dose of VOWST with a positive stool test for C. difficile
    Retreatment spacing rulePrior VOWST course must have been at least 12 days and not more than 8 weeks prior to being eligible for another course
    Initial eligibility branchInitial use for patients who have completed antibiotic treatment for recurrent CDI (at least 3 CDI episodes)
    VYALEV motor 'off' time definition
    VYALEV 'off' time definitionMotor symptoms uncontrolled when average off time ≥2.5 hours/day over 3 consecutive days, with minimum of 2 hours each day
    Levodopa responsiveness requirementPatient must be responsive to levodopa and on at least 400 mg/day of levodopa
    PrescriberInitial prescribing by or in consultation with a neurologist
    Products Affected (list)
    Products affected — core familiesSAFESNAP insulin syringes and TECHLITE syringes are listed repeatedly as affected products
    Common needle/gauge entriesTECHLITE 0.3 mL 31Gx6mm and 31Gx8mm; TECHLITE 0.5 mL 30Gx12mm; SAFESNAP INS SYR UNITS-100 0.5 mL 30Gx5/16" appear across listings
    Pack configurationsEntries include unit pack descriptors such as UNITS-100 and package groupings like 10x10
    Product pack description repeated
    Pack descriptor repeatedSAFESNAP INS SYR UNITS-100 appears repeatedly as the pack descriptor for listed syringe SKUs
    Example listingSAFESNAP INS SYR UNITS-100 0.5 mL 30G x 5/16" shown with multiple packaging variants (10x10, etc.)
    Association with TECHLITESAFESNAP pack entries are paired with TECHLITE 0.3 mL 31GX6MM/31GX8MM and TECHLITE 0.5 mL 30GX12MM in lists
    TECHLITE and SAFESNAP example listing
    TECHLITE and SAFESNAP exampleTECHLITE 0.3 mL 31GX6MM/31GX8MM and SAFESNAP INS SYR UNITS-100 0.5 mL 30GX5/16" are repeatedly listed together as example affected items
    Multiple repeat entriesDocument repeats these pairings in many product group lines across chunks
    ContextListed items are part of the policy's 'Products Affected' (injection supplies) section and subject to the policy rules
    SAFESNAP INS SYR UNITS-100 listing
    SAFESNAP INS SYR UNITS-100 — SKU listingSAFESNAP INS SYR UNITS-100 0.5 mL 30G x 5/16" shown in multiple pack/quantity variants (including 10x10/UNITS-100 groupings)
    Paired TECHLITE SKUsPairings with TECHLITE 0.3 mL 31GX6MM and 31GX8MM are enumerated alongside SAFESNAP entries
    Policy implicationPresence on the 'Products Affected' list implies subject to the policy's authorization/coverage rules elsewhere in the document
    TECHLITE 0.3 ML listing
    TECHLITE 0.3 mL listingTECHLITE 0.3 mL 31GX6MM and 31GX8MM are listed repeatedly as affected syringe SKUs
    Alternate TECHLITE sizeTECHLITE 0.3 mL 29GX12MM and TECHLITE 0.5 mL 30GX12MM also appear in listings
    Common pairingTECHLITE SKUs commonly paired with SAFESNAP UNITS-100 pack descriptors in product groups
    Products Affected entries
    Products Affected entries — descriptionEntries identify syringe model, volume, needle gauge and length, and pack/unit configurations (e.g., TECHLITE 0.3 mL 31GX6MM; SAFESNAP INS SYR UNITS-100 0.5 mL 30GX5/16")
    Repeated groupingMultiple product group lines repeat the same SKU combinations across chunks
    Intended useItems are injection supplies (insulin syringes, pen needles, alcohol prep pads) included in policy's product list
    Products Affected (SAFESNAP/TECHLITE)
    Products Affected — SAFESNAP & TECHLITESAFESNAP INS SYR UNITS-100 (0.5 mL 30Gx5/16") and TECHLITE 0.3 mL 31GX6MM/31GX8MM are enumerated as affected products
    Multiple pack variantsListings include multiple pack/quantity variants (e.g., 10x10, UNITS-100) for the same SKUs
    Policy notePresence on list implies these specific models/configurations are within scope of product authorization rules
    SAFESNAP descriptive entry
    SAFESNAP descriptive entrySAFESNAP INS SYR UNITS-100 0.5 mL 30G x 5/16" shown with multiple packaging lines
    Repeated presenceItem repeats across multiple chunk lines indicating consistent inclusion in product list
    AssociationOften listed with TECHLITE 0.3 mL 31G variants in the same product grouping
    TECHLITE (needle sizes)
    TECHLITE needle sizesTECHLITE entries include 31G x 6mm and 31G x 8mm for 0.3 mL syringes and 30G x 12mm for 0.5 mL syringes
    Common volumesTECHLITE syringes listed in 0.3 mL and 0.5 mL volumes
    Listing repetitionNeedle sizes and volumes are repeated across product groups throughout the section